At the news
? BULLISHIMPACT 7/10 6-K filed Sep 14, 2026 at 07:04 ET
GSK announced positive registrational data from the ARROS-1 trial evaluating Jideytro (zidesamtinib) in first-line ROS1-positive NSCLC, showing a 94% objective response rate and 90% 12-month progression-free survival. The results support a planned supplemental NDA to the FDA in 2026 to expand the indication from second-line to first-line treatment, which could meaningfully expand the drug's addressable market and peak sales potential.
- 94% objective response rate (ORR) in 94 TKI-naïve patients at 15.2 months median follow-up
- 90% of patients progression-free at 12 months; median PFS not yet reached
- 70% of patients with measurable brain metastases achieved complete intracranial clearance
- Only 1% treatment discontinuation rate due to TRAEs; 11% dose reduction rate
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access